Record ID: MS-N060 · Family: Acupuncture / symptom support · Clinical question: In adults with chemotherapy-induced peripheral neuropathy, does acupuncture improve numbness, pain or functional interference?
Evidence label: Mixed early evidence; the 2026 randomized trial missed its primary numbness endpoint.
Evidence at a glance
- Benefit: Small trials suggest possible improvement in pain or symptom interference, but a 2026 randomized study found no significant difference on its primary numbness outcome.
- Certainty: Low. Samples are small, protocols differ, and some encouraging outcomes were secondary.
- Risk: Usually mild; bruising, bleeding, infection and symptom aggravation are possible.
- Cancer control: Not studied.
What was studied
A 2020 pilot randomized 75 adults with moderate to severe chemotherapy-induced peripheral neuropathy to real acupuncture (27), sham acupuncture (24) or usual care (24) for eight weeks. Pain, tingling and numbness were patient-reported outcomes.
A 2026 randomized trial assigned 48 people with taxane-induced neuropathy to acupuncture (16), press-tack needle therapy (17) or waiting-list control (15), with 12 sessions over 13 weeks. The prespecified primary outcome was change in numbness on a visual analog scale.
What the results show
In the 2020 pilot, eight-week pain change was −1.75 points (95% CI −2.69 to −0.81) with real acupuncture, −0.91 (−2.00 to 0.18) with sham and −0.19 (−1.13 to 0.75) with usual care. As a pilot, it was not a definitive efficacy comparison.
In the 2026 trial, the primary numbness comparison was not significant (P=.6023). Some secondary patient-reported interference and pain outcomes favored the intervention groups. Those secondary signals are hypothesis-generating, not a rescue of the negative primary endpoint. Mild adverse events were reported.
Limits and uncertainty
Both trials were small, relied on subjective outcomes and could not fully blind participants to a procedure. The 2026 study’s group sizes were 15–17. Secondary outcomes and multiple comparisons increase the chance of false-positive findings. Results should not be generalized across all neurotoxic agents, neuropathy grades or acupuncture protocols. The 2026 report was appraised from the PubMed-indexed publication; funding/conflict details not stated in the abstract were not independently verified.
Safety and practical context
Neuropathy can affect balance, falls, driving and the safe use of heat or ice. New or worsening symptoms require oncology review because dose modification and other causes may need attention. Avoid needling through infected, numb, irradiated or compromised skin. Extra caution is needed with thrombocytopenia, neutropenia, anticoagulation, lymphedema risk and implanted devices.
Questions for the care team
- Could another condition be contributing to the neuropathy?
- Would physical or occupational therapy, fall prevention, or evidence-based medication be more appropriate?
- What change would count as worthwhile, and after how many sessions will we reassess?
Sources checked
- 2020 randomized pilot (PMID 32159808; PMCID PMC7066475)
- 2026 randomized acupuncture/press-tack trial (PMID 42527066; DOI 10.21873/anticanres.18331)
- NCCIH acupuncture safety overview
Last literature search: October 18, 2026 · Record appraisal: October 18, 2026
Educational evidence summary, not personal medical advice. This record concerns symptom or supportive care. It does not establish tumor shrinkage, recurrence prevention or longer survival, and it should not delay or replace oncology treatment.
